Latest Conference Articles

August 9th 2016, 5:45pm

International Lung Cancer Congress

The optimal use of emerging assays that characterize molecular abnormalities from plasma in late-stage non–small cell lung cancer will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

August 9th 2016, 5:24pm

International Lung Cancer Congress

Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.

August 9th 2016, 3:20am

International Lung Cancer Congress

The value of PD-L1 expression when using checkpoint inhibitors in non–small cell lung cancer is underscored by the just-announced disappointing progression-free survival findings from the phase III CheckMate-026 study of frontline nivolumab (Opdivo) versus physician's choice of combination chemotherapy.

August 6th 2016, 6:43pm

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the next generation of agents coming down the pipeline in non–small cell lung cancer.

August 6th 2016, 6:11pm

International Lung Cancer Congress

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.

August 6th 2016, 1:03am

International Lung Cancer Congress

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non–small cell lung cancer, although they are not commonly considered while doing mutation testing.

August 6th 2016, 12:15am

International Lung Cancer Congress

Tony Mok, MD, discussed translational advances on the horizon in non-small cell lung cancer during a presentation at the 2016 International Lung Cancer Congress.

August 5th 2016, 11:55pm

International Lung Cancer Congress

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

August 5th 2016, 10:12pm

International Lung Cancer Congress

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.

August 5th 2016, 3:28am

International Lung Cancer Congress

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.

August 5th 2016, 2:48am

International Lung Cancer Congress

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

August 4th 2016, 11:57pm

International Lung Cancer Congress

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

July 8th 2016, 5:50pm

ESMO Gastrointestinal Cancers Congress

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

July 8th 2016, 5:09pm

ESMO Gastrointestinal Cancers Congress

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

July 3rd 2016, 1:17am

ESMO Gastrointestinal Cancers Congress

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

July 3rd 2016, 12:25am

ESMO Gastrointestinal Cancers Congress

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

July 2nd 2016, 8:50pm

ESMO Gastrointestinal Cancers Congress

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

July 1st 2016, 11:07pm

ESMO Gastrointestinal Cancers Congress

Treatment with ARQ-087 demonstrated promising signs of clinical activity with a manageable safety profile for patients with FGFR2 fusion-positive advanced and/or metastatic intrahepatic cholangiocarcinoma.

July 1st 2016, 9:19pm

ESMO Gastrointestinal Cancers Congress

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

July 1st 2016, 8:00pm

ESMO Gastrointestinal Cancers Congress

IMAB362, a novel chimeric IgG1 backbone antibody highly specific for CLDN18.2, extended median overall survival by 4.8 months when added to standard chemotherapy in patients with advanced gastric cancer.